ISOLATION AND STRUCTURE DETERMINATION OF CYANOBACTERIAL ANTITUMOR AGENTS

该实验室计划将提供天然产品样本 NCNPDDG。总共1000种蓝藻(蓝藻)将被 每年用亲脂性和亲水性溶剂提取 系统。这些摘录将提交给韦恩州立大学 分析。显示实体瘤和/或肿瘤选择性的提取物 活性将被分级，这样活性化合物就可以被提纯 并确认了身份。将给予符合以下条件的提取液最高优先级 对抗药性实体瘤很有效。我们预计这大约是 0.5%的提取物将显示出值得追求的活动。纵向扩展 然后，将继续进行批次，以提供足够的体内材料 测试。所识别的有源组件将启动模拟 合成程序以及搜索两个Eli的库存 礼来公司和NCI公司进行类比测试。每个人大约1个纯化的化合物 预计明年将开始药理学研究和机制研究 行动研究的一部分。

This Laboratory Program will provide natural product samples for the NCNPDDG. A total of 1,000 blue-green algae (cyanobacteria) will be extracted each year with both a lipophilic and a hydrophilic solvent system. These extracts will be submitted to Wayne State University for analysis. Extracts which exhibit solid tumor and/or tumor selective activity will be fractionated so that the active compound can be purified and identified. Highest priority will be given to those extracts that are active against drug-resistant solid tumors. We expect that about 0.5% of the extracts will demonstrate activity worth pursuing. Scale-up batches will then be pursued to provide sufficient material for in vivo testing. The identified active component will initiate an analog synthesis program as well as a search through the inventories of both Eli Lilly and NCI for analogs to test. Approximately 1 purified compound per year is expected to begin pharmacological studies as well as mechanism of action studies.